Skip to main content
Pharmicell Co.,Ltd. logo

Pharmicell Co.,Ltd. — Investor Relations & Filings

Ticker · 005690 ISIN · KR7005690003 KO Manufacturing
Open in API
Filings indexed 278 across all filing types
Latest filing 2026-06-09 Investor Presentation
Country KR South Korea
Listing KO 005690

About Pharmicell Co.,Ltd.

https://www.pharmicell.com/eng/

Pharmicell Co., Ltd. is a biopharmaceutical company specializing in stem cell technology and advanced bio-based materials. The company is a pioneer in regenerative medicine, having developed Hearticellgram-AMI, the world's first approved stem cell therapy for acute myocardial infarction. Its core business includes the development of stem cell therapeutics, a stem cell banking service for adult and cord blood cells, and a line of cosmetics based on stem cell culture media. A significant division focuses on fine chemicals, manufacturing and supplying critical raw materials for the pharmaceutical industry, such as nucleosides, mPEGs, and oligonucleotides for gene therapies. The company also produces eco-friendly flame retardants for industrial use.

Recent filings

Filing Released Lang Actions
기업설명회(IR)개최(안내공시)
Investor Presentation Classification · 80% confidence The document is a Korean regulatory announcement outlining the date, method, and details of a corporate investor relations presentation (“기업설명회(IR) 개최”). It provides event logistics, agenda, and where IR materials will be posted afterward. This fits the definition of an Investor Presentation notice. There is no actual financial data or report attached, but it is clearly an IR presentation event disclosure, corresponding to filing category IP.
2026-06-09 Korean
기업지배구조보고서공시
Governance Information Classification · 92% confidence The document is a detailed Corporate Governance Report (기업지배구조보고서) containing the company’s governance policies, board structure, committee membership, compliance with governance core indicators, shareholder meeting procedures, and other internal governance disclosures. This aligns precisely with the Governance Information category (CGR).
2026-06-01 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 65% confidence The document is a corporate disclosure in Korean announcing the signing of a single sales and supply contract, detailing counterparty, contract amount, period, and conditions. It is not an annual or interim report, earnings release, financing update, management change, or any specific category; it is a general regulatory announcement of a contract award. Therefore it falls under the fallback category Regulatory Filings (RNS).
2026-05-27 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is a Korean 분기보고서 (59th quarterly report) covering the period 2026-01-01 to 2026-03-31, containing detailed financial statements, notes, and management discussion. This is a comprehensive interim/quarterly report, matching the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-12 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 85% confidence The document is a regulatory filing disclosing the grant (and subsequent correction) of stock options (“주식매수선택권 부여”) by the company to its directors and employees. This constitutes an issuance of new share-based instruments and a change in capital structure rather than a pure financial report or management presentation. Under the classification scheme, announcements of new share issues or capital changes, including option grants, fall under Share Issue/Capital Change (SHA).
2026-05-12 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 90% confidence The document is a contract announcement regarding a single sales and supply agreement between the company and another party. It details contract amount, counterpart, contract period, and payment terms. There is no indication of financial statements, management discussion, or regulatory filings. The content fits the description of a Capital/Financing Update (CAP) as it relates to a significant contract affecting company revenue and operations, but it is not a financing activity like fundraising or capital structure change. However, since it is a sales/supply contract announcement, it is best classified under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2026-05-08 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.